Literature DB >> 18448561

Histologic alterations from neoadjuvant chemotherapy in high-grade extremity soft tissue sarcoma: clinicopathological correlation.

David R Lucas1, Malti P Kshirsagar, J Sybil Biermann, Merlin R Hamre, Dafydd G Thomas, Scott M Schuetze, Laurence H Baker.   

Abstract

Histologic response to chemotherapy is generally regarded as an independent prognostic variable in bone sarcomas, both osteosarcoma and Ewing's sarcoma. In soft tissue sarcomas, however, descriptions of histologic alterations from chemotherapy and correlative outcome studies are much more limited. Herein we report clinicopathological findings from a homogeneously treated group of 31 patients with tumor stage T2 grade 3 extremity soft tissue sarcomas treated with the same neoadjuvant chemotherapy followed by surgical excision, treated by the same medical oncologist and orthopedic surgeon. Histologic response to therapy was evaluated by multiple parameters using a semiquantitative grading system. Based upon the percentage of post-treatment viable tumor, tumors were arbitrarily categorized similarly to Huvos score as showing excellent (< or =5% viability), moderate (6%-49% viability), or poor (> or =50% viability) responses. Nineteen percent had excellent, 10% had moderate, and 71% had poor responses. These histologic response groups did not correlate with overall or event-free survival. For example, of the 22 patients showing a "poor" response, 13 were cured. Similarly, other histologic parameters, including percentages of necrosis, fibrosis/hyalinization, and cellular degeneration, did not correlate with outcome. Chemotherapy induces profound tissue alterations in soft tissue sarcomas. However, histologic alteration by itself may not be a reliable prognostic variable. Correlation of all data from clinical, imaging, and pathological observations by a multidisciplinary tumor board should have greater prognostic value than histology alone. Finally, although the histologic grading system used in this study could not be validated, the criteria we employed are simple and reproducible and take into account the major histologic patterns seen after therapy, and would be amenable for use in future studies.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 18448561     DOI: 10.1634/theoncologist.2007-0220

Source DB:  PubMed          Journal:  Oncologist        ISSN: 1083-7159


  11 in total

1.  Megaprosthesis versus Condyle-sparing intercalary allograft: distal femoral sarcoma.

Authors:  Melissa N Zimel; Amy M Cizik; Timothy B Rapp; Jason S Weisstein; Ernest U Conrad
Journal:  Clin Orthop Relat Res       Date:  2009-08-07       Impact factor: 4.176

2.  Prognostic significance of treatment-induced pathologic necrosis in extremity and truncal soft tissue sarcoma after neoadjuvant chemoradiotherapy.

Authors:  John T Mullen; Francis J Hornicek; David C Harmon; Kevin A Raskin; Yen-Lin Chen; Jackie Szymonifka; Beow Y Yeap; Edwin Choy; Thomas F DeLaney; G Petur Nielsen
Journal:  Cancer       Date:  2014-07-31       Impact factor: 6.860

3.  Local tumour response to neoadjuvant therapy with 2-aminoethyl dihydrogen phosphate in dogs with soft tissue sarcoma.

Authors:  Patrícia Ferreira de Castro; Durvanei Augusto Maria; Ana Carolina Brandão de Campos Fonseca Pinto; Geni Cristina Fonseca Patricio; Julia Maria Matera
Journal:  Vet Med Sci       Date:  2022-02-22

4.  Prognostic relevance of the mitotic count and the amount of viable tumour after neoadjuvant chemotherapy for primary, localised, high-grade soft tissue sarcoma.

Authors:  D Andreou; M Werner; D Pink; F Traub; M Schuler; G Gosheger; B Jobke; P Reichardt; P U Tunn
Journal:  Br J Cancer       Date:  2014-12-23       Impact factor: 7.640

5.  Intraoperative imaging identifies thymoma margins following neoadjuvant chemotherapy.

Authors:  Jane J Keating; Sarah Nims; Ollin Venegas; Jack Jiang; David Holt; John C Kucharczuk; Charuhas Deshpande; Sunil Singhal
Journal:  Oncotarget       Date:  2016-01-19

6.  Metabolomics of Therapy Response in Preclinical Glioblastoma: A Multi-Slice MRSI-Based Volumetric Analysis for Noninvasive Assessment of Temozolomide Treatment.

Authors:  Nuria Arias-Ramos; Laura Ferrer-Font; Silvia Lope-Piedrafita; Victor Mocioiu; Margarida Julià-Sapé; Martí Pumarola; Carles Arús; Ana Paula Candiota
Journal:  Metabolites       Date:  2017-05-18

7.  Preoperative evaluation of the efficacy of radio-hyperthermo-chemotherapy for soft tissue sarcoma in a case series.

Authors:  Hisaki Aiba; Satoshi Yamada; Jun Mizutani; Norio Yamamoto; Hideki Okamoto; Katsuhiro Hayashi; Hiroaki Kimura; Akihiko Takeuchi; Shinji Miwa; Takashi Higuchi; Kensaku Abe; Yuta Taniguchi; Yoshihiro Araki; Hiroyuki Tsuchiya; Takanobu Otsuka
Journal:  PLoS One       Date:  2018-04-16       Impact factor: 3.240

8.  Myxoid Liposarcoma: Treatment Outcomes from Chemotherapy and Radiation Therapy.

Authors:  Varun Chowdhry; Saveli Goldberg; Thomas F DeLaney; Gregory M Cote; Ivan Chebib; Jason Kim; Santiago A Lozano-Calderón; Karen De Amorim Bernstein
Journal:  Sarcoma       Date:  2018-11-01

Review 9.  Microenvironmental Targets in Sarcoma.

Authors:  Monika Ehnman; Olle Larsson
Journal:  Front Oncol       Date:  2015-11-04       Impact factor: 6.244

10.  Tumor grade in soft-tissue sarcoma: Prediction with magnetic resonance imaging texture analysis.

Authors:  Ji Hyun Hong; Won-Hee Jee; Chan-Kwon Jung; Yang-Guk Chung
Journal:  Medicine (Baltimore)       Date:  2020-07-02       Impact factor: 1.817

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.